Skip to main content

Table 3 Kaplan-Meier estimates of progression free survival for all patients and for patients in Heng intermediate and poor risk factor groups*

From: Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Patient group Number of patients at risk Median time to progression or death Months (95% CI)
Month 0 3 6 9 12 15 18 21 24 27 30 33 36
All patients (n = 21) 21 21 15 12 10 8 7 6 4 4 3 1 1 11.2 (6, 19.4)
Heng intermediate risk group (n = 11) 11 11 11 9 8 6 6 5 4 4 3 1 1 19.4 (7.2, 38.1)
Heng poor risk group (n = 10) 10 10 4 3 2 2 1 1 0 0 0 0 0 5.8 (4.3, 11.2)
  1. *Similar results were obtained for MSKCC intermediate (14.9 months) and poor (5.7 months) risk factor groups.
  2. CI = confidence interval.